drugset / Trial / NCT00555620
Study Of Sunitinib In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of the study is to determine the safe and tolerable doses of sunitinib given together with either cisplatin and capecitabine or oxaliplatin and capecitabine in patients who have advanced gastric cancer who have not received prior chemotherapy for their advanced cancer
Timeline
- Start
- 2008-05
- Primary completion
- 2010-08
- Completion
- 2011-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 800 mg/m2 | Oral |
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Subject | Cisplatin | Other / unclassified | 80 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 110 mg/m2 | Intravenous |
| Subject | Sunitinib | Small molecule | 25 mg | Oral |
| Subject | Sunitinib | Small molecule | 37.5 mg | Oral |